期刊
JOURNAL OF CLINICAL LIPIDOLOGY
卷 11, 期 5, 页码 1152-1160出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2017.07.010
关键词
Omega-3 fatty acids; Fish oil; Eicosapentaenoic acid; EPA; Docosahexaenoic acid; DHA; Cardiac death; Meta-analysis
资金
- Amarin
- Amgen
- AstraZeneca
- DSM
- Global Organization for EPA
- Global Organization for and DHA Omega-3s
- Kowa Pharmaceuticals
- Matinas BioPharma
- Pharmavite
- Regeneron
- Sancilio and Co
- Amgen Inc
- Kowa
- Merck
- RegeneronSanofi
- Gemphire Therapeutics, Inc
BACKGROUND: Randomized controlled trials (RCTs) assessing use of long-chain omega-3 polyunsaturated fatty acids (LC-OM3), primarily eicosapentaenoic acid, and/or docosahexaenoic acid have shown mixed results. OBJECTIVE: The objectives of the study were to update and further explore the available RCT data regarding LC-OM3 supplementation and risk for cardiac death and to propose testable hypotheses for the mixed results obtained in RCTs regarding supplemental LC-OM3 use and cardiac risk. METHODS: A literature search was conducted using PubMed and Ovid/MEDLINE for RCTs assessing LC-OM3 supplements or pharmaceuticals with intervention periods of at least 6 months and reporting on the outcome of cardiac death. Meta-analysis was used to compare cumulative frequencies of cardiac death events between the LC-OM3 and control groups, including sensitivity and subset analyses. RESULTS: Fourteen RCTs were identified for the primary analysis (71,899 subjects). In the LC-OM3 arms, 1613 cardiac deaths were recorded (4.48% of subjects), compared with 1746 cardiac deaths in the control groups (4.87% of subjects). The pooled relative risk estimate showed an 8.0% (95% confidence interval 1.6%, 13.9%, P = .015) lower risk in the LC-OM3 arms vs controls. Subset analyses showed numerically larger effects (12.9%-29.1% lower risks, all P < .05) in subsets of RCTs with eicosapentaenoic acid + docosahexaenoic acid dosages >1 g/d and higher risk samples (secondary prevention, baseline mean or median triglycerides mg/dL, low-density lipoprotein cholesterol >= 130 mg/dL, statin use <40% of subjects). Heterogeneity was low (I-2 <= 15.5%, P > .05) for the primary and subset analyses. CONCLUSION: LC-OM3 supplementation is associated with a modest reduction in cardiac death. (C) 2017 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据